Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fibroblast activation protein-α expression in fibroblasts is common in the tumor microenvironment of colorectal cancer and may serve as a therapeutic target.
Greimelmaier K, Klopp N, Mairinger E, Wessolly M, Borchert S, Steinborn J, Schmid KW, Wohlschlaeger J, Mairinger FD. Greimelmaier K, et al. Among authors: wohlschlaeger j. Pathol Oncol Res. 2023 Aug 8;29:1611163. doi: 10.3389/pore.2023.1611163. eCollection 2023. Pathol Oncol Res. 2023. PMID: 37614665 Free PMC article.
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
Schmitz KJ, Grabellus F, Callies R, Otterbach F, Wohlschlaeger J, Levkau B, Kimmig R, Schmid KW, Baba HA. Schmitz KJ, et al. Among authors: wohlschlaeger j. Breast Cancer Res. 2005;7(2):R194-203. doi: 10.1186/bcr977. Epub 2005 Jan 7. Breast Cancer Res. 2005. PMID: 15743500 Free PMC article.
Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways.
Schmitz KJ, Callies R, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS, Takeda A, Schmid KW, Baba HA. Schmitz KJ, et al. Among authors: wohlschlaeger j. J Clin Pathol. 2006 Jul;59(7):685-91. doi: 10.1136/jcp.2005.030650. Epub 2006 Feb 23. J Clin Pathol. 2006. PMID: 16497869 Free PMC article.
No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia.
Riemann K, Becker L, Struwe H, Nückel H, Dührsen U, Alakus H, Winde G, Neuhäuser M, Rübben H, Schmitz KJ, Wohlschlaeger J, Schmid KW, Siffert W. Riemann K, et al. Among authors: wohlschlaeger j. Pharmacogenet Genomics. 2006 Nov;16(11):783-8. doi: 10.1097/01.fpc.0000230414.74726.f6. Pharmacogenet Genomics. 2006. PMID: 17047486
114 results